Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma

Naruse, Tomofumi; Yanamoto, Souichi; Otsuru, Mitsunobu; Yamakawa, Nobuhiro; Kirita, Tadaaki; Shintani, Yukari; Matsumura, Tatsushi; Okura, Masaya; Sasaki, Makoto; Ota, Yoshihide; Yamada, Shin‐ichi; Kitamura, Hiroshi; Umeda, Masahiro

doi:10.21873/anticanres.15395

Cited by 8 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overall response rate (ORR) in these reports was 16-58%, which was different from previous study (9)(10)(11). In contrast, the 1-year OS of salvage surgery was approximately 50% (5,6) and 1-year OS of chemotherapy with Cmab (EXTREME regimen and Cmab plus paclitaxel) was approximately 40% in recurrent or metastatic (R/M) OSCC (12,13). Meanwhile, the ORRs for the EXTREME regimen and Cmab plus paclitaxel were 46.2 and 48.4%, respectively.…”

Section: Discussioncontrasting

confidence: 69%

Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series

et al. 2022

View full text Add to dashboard Cite

Salvage surgery for recurrent oral squamous cell carcinoma (OSCC) often leads to a poor quality of life (QOL). The present study described three cases that resulted in favorable locoregional control with cetuximab in combination with radiotherapy (Cmab + RT). Case 1 had regional recurrence of OSCC at the lower right mastoid area 4 months after primary surgery. Case 2 had regional recurrence of OSCC at the parotid area 7 months after primary surgery. Case 3 had local recurrence of OSCC at the masticatory muscle and Rouviere's lymph nodes 1 year and 3 months after primary surgery. In all cases, Cmab + RT was performed, and disease-free survival was confirmed 4 months, 2 years and 6 months, and 10 months after Cmab + RT, respectively. Immunohistochemically, all resected tumors had no expression of 110-kDa catalytic subunit of class IA phosphatidylinositol 3-kinase (PI3Kp110α). In conclusion, if salvage surgery for recurrent OSCC results in a significantly low QOL, then shifting to chemoradiotherapy may be appropriate as a treatment strategy. In addition, strong evidence indicated that PI3Kp110α expression is associated with Cmab therapy efficacy.

show abstract

Section: Discussioncontrasting

confidence: 69%

Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Immunostaining with anti-vascular endothelial growth factor (VEGF) antibody (Cat. No: 6C0529, VEGF A) was performed for detection of the angiogenesis progress (n=3) at day 21 post wounding (31). Masson trichrome staining was performed on tissues on day 21 post wounding to determine the maturity and area percentage of the deposited collagen fibers (n=3).…”

Section: Histological and Immunohistochemical Analysismentioning

confidence: 99%

The combined effect of the human umbilical cord blood with chitosan scaffold on the full-thickness wound healing process in rats

El-Shaer

Badr

AlSadek

2023

IJVS

View full text Add to dashboard Cite

This study aimed to investigate the role of a low dose of human umbilical cord blood mesenchymal stem cells (HUCB-MSCs) with chitosan scaffold (ChSc) on the progress of the cutaneous wound healing process in male Albino rats. A full-thickness cutaneous wound with a circular shape with a diameter of about 2 cm was induced on the dorsum of thirty-six Albino male rats, divided into four groups: the first group, the wounds were left without treatment as a control group. In the second group, the wounds were covered by freeze-dried ChSc. While in the third group, the wounds were treated through injection of the HUCB-MSCs intradermally, and in the fourth group, the ChSc seeded with HUCB-MSCs were used together to treat the wounds. The progress of wound healing was monitored by histological, immunohistochemical, and biochemical assays for all experimental groups at 3, 8, and 21 postoperative days. Both ChSc and the low dose of HUCB-MSCs alone performed moderate healing progress. The (HUCB-MSCs) ChSc group exhibited an increased healing rate more than the other groups and reported an appropriate collagen deposition without scarring signs, effective mast cell regulation, and well vascularization. In conclusion, the fourth group (the HUCB-MSCs with ChSc) improved the healing process, revealing the highest healing rate and performance without complications.

show abstract

“…Notably, overexpression of EGFR has been detected in more than 27.9% of OSCC cases and is associated with lymph node metastasis (Huang et al, 2009). An antibody‐based EGFR‐targeted therapy is clinically available for the treatment of patients with OSCC, and the targeted therapy combined with typical chemotherapies was reported to contribute to improved survival compared with mono treatment using chemotherapeutics (Fukumoto et al, 2021; Naruse et al, 2021; Yanamoto et al, 2018). Therefore, the development of novel therapeutic agents targeting specific molecules is one of the biggest challenges to achieve the better prognosis of and maintaining the quality of life of patients with OSCC.…”

Section: Introductionmentioning

confidence: 99%

“…An antibody-based EGFR-targeted therapy is clinically available for the treatment of patients with OSCC, and the targeted therapy combined with typical chemotherapies was reported to contribute to improved survival compared with mono treatment using chemotherapeutics (Fukumoto et al, 2021;Naruse et al, 2021;Yanamoto et al, 2018).…”

mentioning

confidence: 99%

PDZ‐binding kinase inhibitor OTS514 suppresses the proliferation of oral squamous carcinoma cells

et al. 2023

View full text Add to dashboard Cite

ObjectivePDZ‐binding kinase (PBK) has been reported as a poor prognostic factor and is a promising molecular target for anticancer therapeutics. Here, we aimed to investigate the effect of specific PBK inhibitor OTS514 on the survival of OSCC cells.MethodsFour OSCC cell lines (HSC‐2, HSC‐3, SAS, and OSC‐19) were used to examine the effect of OTS514 on cell survival and apoptosis. DNA microarray analysis was conducted to investigate the effect of OTS514 on gene expression in OSCC cells. Gene set enrichment analysis was performed to identify molecular signatures related to the antiproliferative effect of OTS514.ResultsOTS514 decreased the cell survival of OSCC cells dose‐dependently, and administration of OTS514 readily suppressed the HSC‐2‐derived tumor growth in immunodeficient mice. Treatment with OTS514 significantly increased the number of apoptotic cells and caspase‐3/7 activity. Importantly, OTS514 suppressed the expression of E2F target genes with a marked decrease in protein levels of E2F1, a transcriptional factor. Moreover, TP53 knockdown attenuated OTS514‐induced apoptosis.ConclusionOTS514 suppressed the proliferation of OSCC cells by downregulating the expression of E2F target genes and induced apoptosis by mediating the p53 signaling pathway. These results highlight the clinical application of PBK inhibitors in the development of molecular‐targeted therapeutics against OSCC.

show abstract

Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma

Cited by 8 publications

References 21 publications

Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series

Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series

The combined effect of the human umbilical cord blood with chitosan scaffold on the full-thickness wound healing process in rats

PDZ‐binding kinase inhibitor OTS514 suppresses the proliferation of oral squamous carcinoma cells

Contact Info

Product

Resources

About